T-Cell Sequencing Reveals Celiac Disease Signatures for Earlier Diagnosis & Monitoring

New Blood Test Offers Hope for Earlier, Less Invasive Celiac Disease Diagnosis

A new study suggests a simple blood test could offer a significant advancement in the diagnosis and monitoring of celiac disease (CD), a chronic autoimmune disorder triggered by gluten ingestion. Currently, diagnosis relies on a combination of serological testing and, crucially, an intestinal biopsy – a process that can be invasive and burdensome for patients.

Celiac disease affects roughly one percent of the global population, characterized by an immune attack on the small intestine in genetically predisposed individuals. This leads to damage of the small bowel mucosa, causing malabsorption and a range of gastrointestinal symptoms, including chronic diarrhea, abdominal pain, weight loss, and, in children, impaired growth. However, recent studies suggest the actual prevalence may be significantly higher, reaching up to three percent in certain populations, indicating a substantial number of undiagnosed cases.

The journey to diagnosis is often lengthy, with patients experiencing significant delays before receiving a definitive answer. Research published in the British Journal of General Practice found that adults with CD frequently face prolonged diagnostic delays, with some studies estimating an average wait time of 13 years. These delays can negatively impact quality of life and potentially lead to long-term health consequences, such as impaired bone health and an increased risk of malignancy.

Understanding the Role of T Cells

Celiac disease is fundamentally driven by an immune response involving T cells. In susceptible individuals, gluten triggers CD4⁺ T cells in the intestine, initiating an immune cascade that damages the intestinal lining. While research has traditionally focused on these gluten-reactive T cells within the gut, recent investigations are turning attention to the potential of analyzing T cells circulating in the bloodstream.

Researchers from Adaptive Biotechnologies, in collaboration with Mayo Clinic and other institutions, have identified shared T-cell receptor (TCR) signatures in the blood of individuals with celiac disease. These signatures effectively distinguish patients from healthy controls, and importantly, are detectable even when patients are not actively consuming gluten.

“By sequencing an individual’s TCR repertoire, we get a full, accurate picture of that person’s T cell response to disease antigens,” explained Rebecca Elyanow, Associate Principal Computational Biologist at Adaptive, to Drug Discovery News. This approach offers a more comprehensive view of the immune response compared to traditional tests that only capture antibodies or tissue changes at a single point in time.

How TCR Sequencing Works

The study involved high-throughput TCR-beta sequencing on blood samples from over 1,600 biopsy-confirmed celiac disease patients, including those adhering to a long-term gluten-free diet, and compared them to over 1,100 healthy controls. Researchers identified hundreds of shared, disease-associated TCRs specifically enriched in patients with CD. The persistence of these signatures even after prolonged gluten-free diets suggests they represent long-lived memory T-cell populations.

The concept of “public” TCRs, or shared TCR sequences, may seem counterintuitive given the vast diversity of the adaptive immune system. However, biases in receptor generation and selection can lead to the recurrence of certain sequences across individuals, reflecting common antigen exposures or underlying disease processes. The researchers found that the celiac-associated TCRs they identified were specifically enriched in patients compared to controls and persisted even after gluten removal.

Implications for Diagnosis and Monitoring

The potential for a non-invasive, blood-based diagnostic test is a major benefit. The identified TCR signatures demonstrate a strong correlation with disease status and the severity of intestinal damage, raising the possibility of using TCR sequencing as a sensitive biomarker for disease activity. “Our data indicates that TCR sequencing could potentially be used as a non-invasive option to quantify and longitudinally monitor the level of these disease-specific TCRs,” Elyanow stated.

Beyond diagnosis, TCR sequencing could also play a crucial role in clinical trials and disease monitoring. Tracking changes in disease-associated T cell populations could provide valuable insights into treatment efficacy, potentially allowing for earlier assessment of therapeutic response than relying solely on clinical symptoms.

“Many pharma and biotech companies are already using our TCR sequencing assay in clinical trials to understand patients’ T-cell responses before and after therapy,” Elyanow added. “As drugs currently under development for celiac disease become available, our CD T cell signature could be used to monitor treatment response by measuring the reduction or elimination of these pathogenic T cells.”

Expanding the Approach to Other Autoimmune Diseases

The principles behind this research extend beyond celiac disease. Similar TCR-based approaches are showing promise in other autoimmune disorders, and the use of immune repertoire signatures as diagnostic and prognostic biomarkers is gaining momentum across various fields. Research has demonstrated the potential of this approach in classifying complex conditions like lupus and multiple sclerosis.

For patients, this could translate to earlier diagnosis, fewer invasive procedures, and more personalized treatment strategies. For clinicians and researchers, TCR sequencing offers a deeper understanding of the underlying biology of autoimmune diseases, paving the way for more targeted and effective therapies. As the field continues to evolve, this technology may revolutionize the way these conditions are diagnosed, monitored, and treated.